Department of Laboratory Medicine, Affiliated Hospital of North Sichuan Medical College, Nanchong 637000, Sichuan Province, China.
Department of Laboratory Medicine, Affiliated Sichuan Ba-Yi Rehabilitation Center of Chengdu University of TCM, Chengdu 610000, Sichuan Province, China.
World J Gastroenterol. 2019 Sep 28;25(36):5515-5529. doi: 10.3748/wjg.v25.i36.5515.
Researchers have investigated the diagnostic value of protein induced by vitamin K absence or antagonist II (PIVKA-II) and alpha-fetoprotein (AFP) in hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC), and obtained abundant clinical diagnostic data. However, PIVKA-II and AFP have unsatisfactory specificity and sensitivity in the diagnosis of early-stage HBV-related HCC. Gamma-glutamyltransferase (γ-GT) and aspartate aminotransferase (AST) are common biomarkers for evaluating liver function, and we hypothesized that the γ-GT/AST ratio in combination with PIVKA-II and AFP would improve the diagnosis of early-stage HBV-related HCC.
To evaluate the diagnostic value of γ-GT/AST ratio alone or in combination with PIVKA-II and AFP in HBV-related HCC.
Serum levels of γ-GT, AST, PIVKA-II, and AFP were detected and analysed in 176 patients with HBV-related HCC and in 359 patients with chronic hepatitis B. According to tumour size and serum level of HBV DNA, HBV-related HCC patients were divided into the following categories: Early-stage HCC patients, HCC patients, HBV DNA positive (HBV DNA+) HCC patients, and HBV DNA negative (HBV DNA-) HCC patients. Receiver-operating characteristic (ROC) curves were used to analyse and compare the diagnostic value of the single and combined detection of various biomarkers in different types of HBV-related HCC.
Tumour size was positively correlated with serum levels of PIVKA-II and AFP in HCC patients ( = 0.529, < 0.001 and = 0.270, < 0.001, respectively), but there was no correlation between tumour size and the γ-GT/AST ratio ( = 0.073, = 0.336). The areas under the receiver-operating characteristic curves (AUROCs) of the γ-GT/AST ratio in early-stage HCC patients, HBV DNA+ HCC patients and HBV DNA- HCC patients were not significantly different from that in the total HCC patients (0.754, 0.802, and 0.705 0.779, respectively; > 0.05). When PIVKA-II was combined with the γ-GT/AST ratio in the diagnosis of early-stage HCC, HCC, and HBV DNA+ HCC, the AUROCs of PIVKA-II increased, with values of 0.857 0.835, 0.925 0.913, and 0.958 0.954, respectively. When AFP was combined with the γ-GT/AST ratio in the diagnosis of early-stage HCC, HCC, HBV DNA+ HCC, and HBV DNA- HCC, the AUROCs of AFP increased, with values of 0.757 0.621, 0.837 0.744, 0.868 0.757, and 0.840 0.828, respectively.
The γ-GT/AST ratio may be better than PIVKA-II and AFP in the diagnosis of early-stage HBV-related HCC, and its combination with PIVKA-II and AFP can improve the diagnostic value for HBV-related HCC.
研究人员已经研究了维生素 K 拮抗剂 II(PIVKA-II)和甲胎蛋白(AFP)诱导的蛋白在乙型肝炎病毒(HBV)相关肝细胞癌(HCC)中的诊断价值,并获得了丰富的临床诊断数据。然而,PIVKA-II 和 AFP 在诊断早期 HBV 相关 HCC 时特异性和灵敏度均不理想。γ-谷氨酰转移酶(γ-GT)和天冬氨酸氨基转移酶(AST)是评估肝功能的常用生物标志物,我们假设 γ-GT/AST 比值与 PIVKA-II 和 AFP 联合使用将改善早期 HBV 相关 HCC 的诊断。
评估 γ-GT/AST 比值单独或与 PIVKA-II 和 AFP 联合用于 HBV 相关 HCC 的诊断价值。
检测和分析 176 例 HBV 相关 HCC 患者和 359 例慢性乙型肝炎患者的 γ-GT、AST、PIVKA-II 和 AFP 血清水平。根据肿瘤大小和 HBV DNA 血清水平,将 HBV 相关 HCC 患者分为以下几类:早期 HCC 患者、HCC 患者、HBV DNA 阳性(HBV DNA+)HCC 患者和 HBV DNA 阴性(HBV DNA-)HCC 患者。采用受试者工作特征(ROC)曲线分析和比较各种生物标志物在不同类型 HBV 相关 HCC 中的单检和联合检测的诊断价值。
肿瘤大小与 HCC 患者的 PIVKA-II 和 AFP 血清水平呈正相关(=0.529,<0.001 和=0.270,<0.001),但与 γ-GT/AST 比值无相关性(=0.073,=0.336)。γ-GT/AST 比值在早期 HCC 患者、HBV DNA+HCC 患者和 HBV DNA-HCC 患者中的 ROC 曲线下面积(AUROCs)与总 HCC 患者的 AUROCs 无显著差异(0.754、0.802 和 0.705 与 0.779,分别;>0.05)。当 PIVKA-II 与 γ-GT/AST 比值联合用于诊断早期 HCC、HCC 和 HBV DNA+HCC 时,PIVKA-II 的 AUROCs 增加,分别为 0.857、0.835、0.925 和 0.913、0.958 和 0.954。当 AFP 与 γ-GT/AST 比值联合用于诊断早期 HCC、HCC、HBV DNA+HCC 和 HBV DNA-HCC 时,AFP 的 AUROCs 增加,分别为 0.757、0.621、0.837 和 0.744、0.868 和 0.757、0.840 和 0.828。
γ-GT/AST 比值在诊断早期 HBV 相关 HCC 方面可能优于 PIVKA-II 和 AFP,其与 PIVKA-II 和 AFP 的联合使用可以提高 HBV 相关 HCC 的诊断价值。